|1872||Tokubei Torii established a company named Uenoya, at Sakai-Machi, Yokohama, for import of pharmaceuticals from the West.|
Establishment of Uenoya's research laboratories, and start of dealing in Japanese pharmacopoeial drugs under the Torii brand name.
Uenoya reorganized as Torii Shoten K.K.
|1949(May)||Company name changed to Torii Pharmaceutical Co., Ltd.|
|1963(Apr.)||Torii introduced ALLERGEN (allergenic extracts) an agent developed in-house for allergy diagnosis and immunotherapy.|
|1963(June)||Torii went public with over-the-counter stock transactions at the Tokyo Securities Dealers Association.|
|1977(Oct.)||A new plant constructed at Sakura, Chiba Prefecture, in accordance with GMP (Good Manufacturing Practices ) standards.|
|1990(Apr.)||Current Head Office building completed.|
|1993(Oct.)||Torii's stock listed on the second section of the Tokyo Stock Exchange.|
Torii launched ANTEBATE ointment and cream (betamethasone butyrate propionate), a topical adrenocortical hormone.
|1995(Sept.)||Torii's stock listed on the first section of the Tokyo Stock Exchange.|
|1998(Dec.)||Japan Tobacco Inc.(JT) purchased more than 50% of Torii's stock.|
|1999(Oct.)||JT and Torii established a collaboration arrangement (Torii concentrates on marketing and JT, on R&D.)|
Torii launched the oral antipruritis drug REMITCH CAPSULES (nalfurafine hydrochloride), for which Toray Industries, Inc. obtained manufacturing and marketing approval.
Torii launched Riona Tablets (Ferric Citrate Hydrate) for the treatment of hyperphosphatemia, for which JT obtained manufacturing and marketing approval.
Torii launched “CEDARTOLEN SUBLINGUAL DROP - Japanese Cedar Pollen” a Sublingual Immunotherapy Drug for Japanese Cedar Pollinosis.
Torii launched “MITICURE House Dust Mite Sublingual Tablets” an Allergen Immunotherapy Tablet for House Dust Mite Allergy
Torii Launched “CEDARCURE ® Japanese Cedar Pollen Sublingual Tablets”, an Allergen Immunotherapy Tablet for Japanese Cedar Pollinosis.
Torii launched the CORECTIM (delgocitinib) ,Topical Janus kinase (JAK) inhibitor,for which JT obtained manufacturing and marketing approval.
|2020(July)||Torii transferred Sakura Plant to IWAKI SEIYAKU CO.,LTD..|
Torii launched ENAROY Tablets (enarodustat) for the treatment of Anemia Associated with Chronic Kidney Disease, for which JT obtained manufacturing and marketing approval.
Torii launched ORLADEYO Capsules, a plasma kallikrein inhibitor indicated for the suppression of the attacks in hereditary angioedema (HAE) ,for which OrphanPacific, Inc. obtained manufacturing and marketing approval.